The Intricate Interplay Between Syntaxins and Tau in Neurodegenerative Diseases

The Intricate Interplay Between Syntaxins and Tau in Neurodegenerative Diseases

Introduction:
Neurodegenerative diseases, such as Alzheimer's disease, are characterized by the accumulation of abnormal protein aggregates in the brain. Tau, a microtubule-associated protein, plays a crucial role in these diseases as it forms insoluble filaments that contribute to disease progression. Recent studies have shed light on the involvement of syntaxins, specifically syntaxin 6 (STX6) and syntaxin 8 (STX8), in the secretion and trafficking of tau. Additionally, post-translational modifications (PTMs) of tau have been found to influence its aggregation and propagation. Understanding the intricate interplay between syntaxins and tau, as well as the impact of PTMs on tau pathology, could provide valuable insights for the development of therapeutic strategies. In this article, we will explore the connection between syntaxins and tau, and the role of PTMs in neurodegenerative diseases.

Syntaxins 6 and 8: Mediators of Tau Secretion and Trafficking:
Syntaxin 8 (STX8) and syntaxin 6 (STX6), members of the SNARE family, have been implicated in the release of tau from cells. HEK293T cells overexpressing STX6 and STX8 showed detectable levels of tau in the culture medium, whereas tau was undetectable in the control group. This suggests that STX6 and STX8 facilitate tau secretion. Interestingly, STX8 is known to be involved in endosomal protein trafficking, raising the possibility of its involvement in tau trafficking and secretion. STX8 localizes to recycling and late endosomes, while STX6 localizes to the trans-Golgi network and early endosomes. Co-localization of tau with STX6 in vesicles further supports the hypothesis that syntaxins play a role in directing tau into secretory pathways. The precise mechanisms underlying this process require further investigation.

Distinct Tau Folds and PTMs: Implications for Aggregation and Propagation:
Tau exists in different conformations or "folds," and these distinct folds have been found to initiate templated seeding, a process by which abnormal tau aggregates induce the aggregation of normal tau. Interestingly, the post-translational modification (PTM) profile of tau remains relatively unchanged upon seeding, suggesting that PTMs are not directly involved in the aggregation process. However, it is worth noting that tau overexpression leads to an excessive level of PTMs. This raises the possibility that tau with excessive PTMs is necessary for aggregation. The presence of PTMs, such as ubiquitination and acetylation, in the filament core region is a prominent feature in patient-derived tau filaments. However, these modifications were below the detection limit in tau extracted from cells expressing heavy-HA1N3R or heavy-HA1N4R, indicating their limited relevance to aggregation. Most phosphorylation sites detected in patient-derived insoluble tau were also present in seeded insoluble tau, with significantly higher abundance in patient-derived tau. This suggests that phosphorylation occurs after aggregation and may contribute to disease progression.

The Role of Incubation Time in PTMs:
Further investigation into the role of PTMs revealed that longer incubation times promoted phosphorylation and deamidation of tau. However, PTMs at lysine residues remained undetectable. This raises the question of why PTMs at lysine residues do not change during the aggregation process. It is possible that other factors contribute to the regulation of lysine PTMs or that they occur at a different stage of tau aggregation.

Actionable Advice:

1. Investigate the role of syntaxins in tau secretion: Further research is needed to understand the precise mechanisms by which syntaxins, particularly STX6 and STX8, facilitate tau secretion and trafficking. This could potentially lead to the development of therapeutic strategies targeting these pathways.
2. Study the impact of PTMs on tau aggregation: Explore the influence of different PTMs, such as phosphorylation, acetylation, and ubiquitination, on tau aggregation and propagation. Understanding the role of PTMs in disease progression could open up new avenues for therapeutic interventions.
3. Examine the effect of incubation time on PTMs: Investigate the changes in PTMs during different stages of tau aggregation by varying the incubation time. This could provide insights into the temporal relationship between PTMs and tau aggregation.

Conclusion:
The interplay between syntaxins and tau, as well as the impact of PTMs on tau aggregation, represents a fascinating area of research in the field of neurodegenerative diseases. Further exploration of these topics could provide valuable insights into the underlying mechanisms of disease progression and pave the way for the development of effective therapeutic strategies. By investigating the role of syntaxins in tau secretion, studying the influence of PTMs on tau aggregation, and examining the effect of incubation time on PTMs, researchers can uncover novel insights into the complex pathology of neurodegenerative diseases.